highlights of my research

1. Electrodeposition of flower-like nickel oxide on CVD-grown graphene to develop an
electrochemical non-enzymatic biosensor
Highlights
We successfully fabricated a NiO/graphene nanocomposite by
electrodeposition of NiO onto the surface of CVD-grown
graphene, which was then used to investigate the nonenzymatic
detection of cholesterol.
The composite electrode detected a range of cholesterol
concentrations from 2 mM to 40 mM with high sensitivity.
Additionally, a low detection limit and a rapid response time
of 0.13 mM and 5 s, respectively, were observed.
J. Mater. Chem. B, 2015, 3, 6301--6309

2. Porous Covalent Triazine Polymer as a Potential Nanocargo for Cancer Therapy and Imaging
Highlights
NCTP and used it as both a potential photosensitizer and pH-responsive nanocarrier
for cancer therapy and imaging.
NCTP-DOX exhibited a higher cytotoxic effect on cancer cells than free DOX and
induced strong senescence at lower concentration.
ACS Appl. Mater. Interfaces, 2016, 8 (14), pp 8947–8955

3. PAMAM/5-fluorouracil drug conjugate for targeting E6 and E7 oncoproteins in cervical
cancer: a combined experimental/in silico approach†
PAMAM/5-FU conjugate binding with E6 and E7 oncoproteins in cervical cancer and
preventing their interactions with the tumor suppressor protein p53 and pRb.
Molecular docking analysis. (a, d) conformational structure (b, e) interaction profile, and
(c, f) RMSD plot of E6 and E7 protein over PAMAM/5-FU conjugate.
Confocal imaging of (a) DAPI stained HeLa cell, (b) FITC-PAMAM/5-FU (c) FITC–
PAMAM/5-FU in HeLa cell, and (d) FITC–5-FU in HeLa cell.
Cytotoxicity analysis of 5-FU and PAMAM/5-FU conjugate over HeLa cells, (b) Western
blotting to evaluate the effects of 5-FU and PAMAM/5-FU conjugate over tumor
suppressor proteins, (c) RBC and WBC count, and (d) Eosinophil count.
Highlights
Molecular docking analysis of PAMAM/5FU with the oncoproteins (E6 and E7) revealed
excellent downregulation activities of the oncoproteins relative to the pure 5-FU.
The effectiveness of PAMAM/5-FU towards cancer killing ability was confirmed by the
down-regulation of tumor oncogenic proteins p53 and pRB.
RSC Adv., 2017,7, 5046-5054